• BioMark Diagnostics received patent allowances from Canada’s CIPO and the European Patent Office for its early-stage lung cancer blood test.
• The liquid-biopsy test targets early detection of non-small cell lung cancer using an algorithm tied to metabolomics-based signatures.
• The company cited validation across more than 15,000 blood samples collected in Quebec, France, and Germany.
• BioMark is preparing a commercial launch later this year while pursuing related patent applications in the US, China, and Japan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMark Diagnostics Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202606230830NEWSFILECNPR____20260623_302429_1) on June 23, 2026, and is solely responsible for the information contained therein.